slotkoers
Korea S.E.
00:00:00 01-07-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
8.410
KRW
|
+1,69%
|
|
-6,03%
|
-32,67%
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
323.319
|
1.048.465
|
468.827
|
245.897
|
176.209
|
Bedrijfswaarde
1 |
300.094
|
940.636
|
398.490
|
145.490
|
116.390
|
K/w-verhouding
|
-3,72
x
|
-24,9
x
|
-13,7
x
|
-4,74
x
|
-3,72
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
-
|
Marktkapitalisatie/omzet
|
7.054
x
|
6.963
x
|
1.039
x
|
17,5
x
|
12,3
x
|
Bedrijfswaarde/omzet
|
6.547
x
|
6.247
x
|
883
x
|
10,3
x
|
8,14
x
|
Bedrijfswaarde/EBITDA
|
-22,6
x
|
-37,4
x
|
-11,9
x
|
-3,03
x
|
-2,49
x
|
Bedrijfswaarde/FCF
|
-
|
-12.258.438
x
|
-23.263.737
x
|
-4.118.887
x
|
-3.699.967
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
-7,94
x
|
9,49
x
|
5,26
x
|
2,55
x
|
2,98
x
|
Aantal aandelen (in duizenden)
|
8.227
|
13.188
|
13.511
|
14.092
|
14.108
|
Referentieprijs
2 |
39.300
|
79.500
|
34.700
|
17.450
|
12.490
|
Datum van publicatie
|
10/03/21
|
10/03/21
|
21/03/22
|
21/03/23
|
20/03/24
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
45,83
|
150,6
|
451,2
|
14.085
|
14.296
|
EBITDA
1 |
-13.251
|
-25.164
|
-33.496
|
-48.051
|
-46.820
|
Bedrijfsresultaat (EBIT)
1 |
-13.821
|
-26.629
|
-36.087
|
-57.512
|
-55.092
|
Operationele Marge
|
-30.155,63%
|
-17.683,84%
|
-7.997,2%
|
-408,34%
|
-385,37%
|
Resultaat voor belastingen (EBT)
1 |
-84.669
|
-31.186
|
-36.004
|
-58.033
|
-51.855
|
Nettowinst (verlies)
1 |
-84.669
|
-30.732
|
-34.117
|
-51.838
|
-47.466
|
Nettomarge
|
-184.731,34%
|
-20.409,23%
|
-7.560,62%
|
-368,05%
|
-332,02%
|
WPA
2 |
-10.562
|
-3.192
|
-2.538
|
-3.683
|
-3.362
|
Free Cash Flow
|
-
|
-76.734
|
-17.129
|
-35.323
|
-31.457
|
FCF-marge
|
-
|
-50.958,36%
|
-3.795,98%
|
-250,79%
|
-220,04%
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
10/03/21
|
10/03/21
|
21/03/22
|
21/03/23
|
20/03/24
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
23.225
|
107.829
|
70.338
|
100.408
|
59.819
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-76.734
|
-17.129
|
-35.323
|
-31.457
|
ROE (netto-inkomsten/eigen vermogen)
|
-
|
-80,9%
|
-31,5%
|
-43,2%
|
-38,4%
|
ROA (netto-inkomsten/totale activa)
|
-
|
-21,3%
|
-17,5%
|
-23,2%
|
-20,6%
|
Totale activa
1 |
-
|
144.097
|
195.207
|
223.686
|
230.940
|
Nettoactief per aandeel
2 |
-4.950
|
8.375
|
6.593
|
6.838
|
4.191
|
Cashflow per aandeel
2 |
2.737
|
7.813
|
2.563
|
5.125
|
3.827
|
Capex
1 |
688
|
1.504
|
2.875
|
6.849
|
18.853
|
Capex/omzet
|
1.500,1%
|
999,1%
|
637,2%
|
48,63%
|
131,88%
|
Datum van publicatie
|
10/03/21
|
10/03/21
|
21/03/22
|
21/03/23
|
20/03/24
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| -32,67% | 91,73 mln. | | +16,59% | 45,51 mld. | | -9,89% | 38,52 mld. | | +38,08% | 38,13 mld. | | +27,12% | 30,74 mld. | | -8,64% | 26,03 mld. | | +11,81% | 25,92 mld. | | +45,08% | 14,13 mld. | | +32,85% | 12,73 mld. | | -7,19% | 11,29 mld. |
Biotechnologie & Medisch Onderzoek - Andere
|